Baudax Bio, Inc.: Nasdaq/NYSE listing notice — Baudax Bio receives Nasdaq delisting notice for negative stockholders' equity

Baudax Bio, Inc.

Reported stockholders' equity of ($19,540,000) as of Sept 30, 2022, below Nasdaq's $2.5M minimum.
Must submit compliance plan by December 30, 2022; if accepted, up to 180 days to regain compliance.
Stock continues trading on Nasdaq Capital Market pending plan review and potential hearing.
Company is evaluating options to resolve deficiency; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Baudax Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 15, 2022, Baudax Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its quarterly report for the quarter ended September 30, 2022, the Company reported stockholders’ equity of ($19,540,000), and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Company

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-22-288951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.